Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Millennium Pharmaceuticals Limited

Osamu Kurasawa

Takuto Kojima

Shinichi Imamura

Hiroshi Banno

Yuya Oguro

Yasutomi Asano

Tzu-Tshin Wong

Yasufumi Miyamoto

Shuji Kitamura

Yasuhiro Hirata

Yuta Tanaka

Misaki Homma

Kazuko Yonemori

Naoki Iwamura

Toru Miyazaki

Ryosuke Arai

Bunnai Saito

Osamu Sano

Masaaki Mori

Tsuneo Oda

Hirokazu Matsumoto

Masanori Baba

Xin Liu

Naoyuki Kanzaki

Osamu Nishimura

Masaaki Hirose

Takahiro Matsumoto

Terufumi Takagi

Naoki Tarui

Shohei Hashiguchi

Yutaka Nakayama

Douglas Robert Cary

Hiroshi Nagabukuro

Jun Fujimoto

Kohji Fukatsu

Manabu Mochizuki

Arai Ryosuke

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

The present invention relates to a compound represented by the formula (I) or (I'): 

Thiazole derivatives

The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Thienopyrimidine as CDC7 kinase inhibitors

The present invention provides a compound represented by the formula: 

Bicyclic piperazine compound having TGR23 antagonistic activity

A novel pyrrolopyridine derivative which is a compound represented by the formula  wherein Ring A represents an optionally substituted pyridine ring; X represents an electron-attracting group; Y represents an optionally substituted divalent Cchain hydrocarbon group; Rrepresents an optionally substituted hydrocarbon group; and Rand Reach independently represents hydrogen, an optionally substituted hydrocarbon group or an optionally-substituted heterocyclic group, or Rand Rmay form an optionally substituted ring in cooperation with the adjacent nitrogen atom, or a salt of the compound. The pyrrolopyridine derivative has vanilloid receptor agonist activity and is useful as medicines such as a preventive/therapeutic agent and analgesic for overactive bladder.

Pyrrolopyridine derivative and use thereof

Urea compounds, process for producing the same and use thereof

Growing community of inventors

Kanagawa, Japan

Osamu Kurasawa